Just a moment, the page is loading...

GSK-29060/625




A double-blind, placebo-controlled multi-centre study to evaluate the efficacy and tolerability of Paroxetine in the treatment of post-stroke depression.
paroxetine
29060/625
Depressive Disorder, Major
Phase 3
An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
May 2014